Search clinical trials for: dacomitinib oral

Total 8205 results

Pfizer

Completed

A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers

Healthy Volunteers

United Kingdom
National Cancer Centre, Singapore
Singapore Translational Cancer Consortium; Genome Institute of Singapore; Cancer...

Recruiting

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumours

Singapore
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Shanghai Chest Hospital

Recruiting

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Non-small Cell Lung Cancer Metastatic | EGF-R Positive Non-Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Not yet recruiting

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
David Piccioni, M.D., Ph.D
Pfizer

Terminated

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Brain Cancer

United States
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Pfizer

Recruiting

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Lung Cancer

Malaysia
Pfizer

Completed

Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers

Healthy

China
Pfizer

Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Healthy | Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

United States
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Pfizer

Completed

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

Healthy Volunteers

Belgium
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Pfizer

Completed

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis (HER-Uro01)

Carcinoma, Squamous Cell | Penile Neoplasms

Italy
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Skin Squamous Cell Cancer

Italy
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Pfizer

Completed

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States
Samsung Medical Center

Recruiting

Central Nervous System(CNS) Efficacy of Dacomitinib

Non Small Cell Lung Cancer | Brain Metastases

Korea, Republic of
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Pfizer

Not yet recruiting

A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Carcinoma, Non-Small-Cell Lung
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Lung Cancer | Lung Cancer Metastatic | EGFR Gene Mutation

United States
British Columbia Cancer Agency

Approved for marketing

18F-FDG PET Imaging in Cardiac Sarcoidosis

Cardiac Sarcoidosis

Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Metastatic Non-small Cell Lung Cancer

United States
Pfizer

Completed

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Neoplasm Metastasis | Carcinoma, Non-Small Cell

United States, France, Spain
Pfizer

Completed

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Metastatic Non Small Cell Lung Cancer

India
The Netherlands Cancer Institute
Pfizer

Unknown

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (M13DAP)

Colorectal Cancer

Netherlands
Fondazione Ricerca Traslazionale

Recruiting

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)

NSCLC

Italy
Eunice Kennedy Shriver National Institute of Child...

Terminated

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

Amenorrhea | Aplastic Anemia | Menorrhagia

United States
Lightpoint Medical Limited
Semmelweis University

Withdrawn

Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery (CLIO)

Gastric Cancer | Pancreatic Cancer | Bile Duct Cancer | Duodenal Cancer

Hungary
Central European Cooperative Oncology Group

Terminated

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Austria
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Burnasyan Federal Medical Biophysical Center

Completed

Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers

Angina Pectoris | Stroke, Not Specified as Hemorrhage or Infarction

Russian Federation
Université de Montréal
St. Justine's Hospital

Terminated

Comparison of Two Oral Myofunctional Reeducation Methods for Children With Obstructive Sleep Apnea (PERSIST-B)

Obstructive Sleep Apnea

Canada
Pfizer

Completed

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Neoplasm

United States, Spain, Canada, Italy, United Kingdom
Estetra
ICON Clinical Research

Completed

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort)

Vasomotor Symptoms | Menopausal Symptoms

United States, Canada
Pulmagen Therapeutics

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

Atopic Asthma

United Kingdom
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Mansoura University

Completed

Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)

Small Bowel Obstruction

Egypt
German Institute of Human Nutrition
Ludwig-Maximilians - University of Munich

Completed

Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1 (ILIAS-1)

Diabetes | Pre-diabetes

Germany
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Brigham and Women's Hospital

Completed

Characterizing Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349

Pharmacokinetics
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
Ain Shams University

Completed

Early Versus Traditional Oral Hydration After Cesarean Section

Gastrointestinal Motility and Defecation Conditions

Egypt
EicOsis Human Health Inc.

Recruiting

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects

Healthy Subjects

New Zealand
Loma Linda University

Completed

Oral Sucrose Versus Glucose for Procedural Pain in Premature Neonates

Neonatal Procedural Pain

United States

Search clinical trials for: dacomitinib oral

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations